How should we assess the clinical and cost effectiveness of histology independent cancer drugs?

Sophie Cooper; Jacoline C. Bouvy; Lawrence Baker; Francois Maignen; Pall Jonsson; Peter Clark; Stephen Palmer; Meindert Boysen; Nick Crabb

doi:10.1136/bmj.l6435

How should we assess the clinical and cost effectiveness of histology independent cancer drugs?

Sophie Cooper^*, Jacoline C. Bouvy, Lawrence Baker, Francois Maignen, Pall Jonsson, Peter Clark, Stephen Palmer, Meindert Boysen, Nick Crabb

^*Corresponding author for this work

Centre for Health Economics

Research output: Contribution to journal › Article › peer-review

Original language	English
Article number	l6435
Journal	The BMJ
Volume	368
DOIs	https://doi.org/10.1136/bmj.l6435
Publication status	Published - 2 Jan 2020

Access to Document

10.1136/bmj.l6435

Cite this

@article{4bc2220a45bd44f79d81707cd18cc603,

title = "How should we assess the clinical and cost effectiveness of histology independent cancer drugs?",

author = "Sophie Cooper and Bouvy, {Jacoline C.} and Lawrence Baker and Francois Maignen and Pall Jonsson and Peter Clark and Stephen Palmer and Meindert Boysen and Nick Crabb",

year = "2020",

month = jan,

day = "2",

doi = "10.1136/bmj.l6435",

language = "English",

volume = "368",

journal = "The BMJ",